Anthony P Mack

Anthony Mack is a seasoned pharma/biotech entrepreneur with 35+ years spanning company formation, capital markets, IP strategy, and strategic alliances. He founded ProSolus (later acquired by Mission Pharmacal), led Scilex with Itochu Chemical Frontier (ITOCHU group) as its largest investor prior to acquisition by a public biopharma, and served as Chairman & CEO of Virpax (NASDAQ: VRPX), completing a 2021 IPO and raising $60M in total (IPO + follow-on), alongside NIH/DoD grants. As President & CEO of Pathways Neuro Pharma, he is advancing durable, CNS-targeted gene therapies for rare pediatric neurological disorders—pairing scientific rigor with a repeatable partnership playbook where strategics invest, join boards, and co-build value. His focus: defensible IP, milestone discipline, and alliances that accelerate development.